Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma

Autor:	Daniel M, Geynisman, Ella X, Du, Xiaoran, Yang, Selvam R, Sendhil, Viviana Del, Tejo, Keith A, Betts, Stephen, Huo
Rok vydání:	2022
Předmět:	Cancer Research Nivolumab Cost of Illness Oncology Cost Savings Antineoplastic Combined Chemotherapy Protocols Sunitinib Humans General Medicine Carcinoma Renal Cell Ipilimumab Drug Costs Kidney Neoplasms
Zdroj:	Future Oncology. 18:1219-1234
ISSN:	1744-8301 1479-6694
Popis:	Aims: To assess grade 3/4 adverse events (AEs) and costs of first-line nivolumab plus ipilimumab versus sunitinib in advanced or metastatic renal cell carcinoma. Methods: Individual patient data from the all treated population in the CheckMate 214 trial (nivolumab plus ipilimumab, n = 547; sunitinib, n = 535) were used to calculate the number of AEs. AE unit costs were obtained from US 2017 Healthcare Cost and Utilization Project and inflated to 2020 values. Results: The proportion of patients experiencing grade 3/4 AEs decreased over time. Patients who received nivolumab plus ipilimumab had lower average per-patient all-cause grade 3/4 AE costs versus sunitinib (12-month: US$15,170 vs US$20,342; 42-month: US$19,096 vs US$27,473). Conclusion: Treatment with nivolumab plus ipilimumab was associated with lower grade 3/4 AE costs than sunitinib.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::266d5aea39b39f6ad03296da75117833 https://doi.org/10.2217/fon-2021-1109 Zobrazit plný text záznamu